Glaukos Corporation - GKOS STOCK NEWS

Glaukos Corporation (NYSE: GKOS) reported a remarkable 147% increase in net sales for Q2 2021, reaching $78.1 million compared to $31.6 million in Q2 2020. Key drivers included glaucoma net sales of $62.7 million and corneal health sales of $15.4 million. The gross margin improved to 77%, while operating expenses rose to $74.6 million. The net loss was reduced to $17.5 million or ($0.38) per diluted share, an improvement from $39.9 million in the previous year. The company expects net sales for 2021 to be between $285 million and $290 million.

Glaukos Corporation (NYSE: GKOS) announced its participation in the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting from July 23–27, 2021, in Las Vegas. The company will sponsor an educational symposium titled “Innovation & Transformation in Glaucoma Management” on July 23, 2021. The event will showcase important presentations on trabecular micro-bypass stents and corneal health, emphasizing Glaukos' commitment to glaucoma and corneal disorder treatments. The company aims to demonstrate its innovative technologies and engage with healthcare professionals throughout the event.

Glaukos Corporation (NYSE: GKOS) will announce its second quarter 2021 financial results on August 5, 2021, after market close. The management team will host a conference call and webcast at 1:30 p.m. PDT to discuss the results. Interested parties can access the live webcast via the company’s investor relations website and participate in the call by dialing the provided numbers and entering the conference ID. Glaukos specializes in innovative therapies for ocular conditions, including glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery.

Glaukos Corporation (NYSE: GKOS) responded to the CMS 2022 Medicare Physician Fee Schedule Proposed Rule released on July 13, 2021. This rule updates reimbursement policies for cataract surgery combined with the insertion of an aqueous drainage device. Two new CPT codes (669X2 and 669X1) will replace existing codes, with Glaukos estimating the 2022 physician fee for 669X2 at approximately $565.23, an increase of $34.25 from the previous fee. The company expressed disappointment over these proposed fees and plans to engage with ophthalmic societies during the public comment period.

Glaukos Corporation (GKOS) has completed patient enrollment and randomization in its FDA Phase 3 clinical trials for the iDose^® TR sustained-release travoprost implant. The two prospective trials involve 1,150 subjects across 89 sites, aiming to assess the safety and efficacy of the iDose TR compared to timolol for treating open-angle glaucoma. Successful trial results are expected to support NDA submission in 2022 and FDA approval in 2023, potentially enhancing patient adherence to glaucoma treatments.

Glaukos Corporation (NYSE: GKOS) has received regulatory approval from Australia's Therapeutic Goods Administration (TGA) for its PRESERFLO MicroShunt. This device is designed to reduce intraocular pressure in patients with primary open-angle glaucoma, providing an alternative to conventional surgeries. Glaukos plans to initiate commercial activities for the MicroShunt in late 2021, targeting a full launch by mid-2022, contingent on reimbursement. The company maintains exclusive commercialization rights for the MicroShunt across several key markets, including Australia and the Americas.

Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will present at the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 4:40 p.m. CDT. The event will be available via live and archived webcast on their Investors website. Glaukos specializes in innovative therapies for glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices like the iStent and its successors. The company's advancements aim to transform treatment paradigms in ophthalmology.

Glaukos Corporation (NYSE: GKOS) announced a development and commercialization license agreement with Santen Pharmaceutical for the PRESERFLO™ MicroShunt, replacing prior agreements. Glaukos gains exclusive commercialization rights in the U.S., Australia, Canada, and Latin America, along with full control over development activities. The MicroShunt, aimed at treating glaucoma, has a PMA application pending with the FDA. Santen will continue to manufacture the device. Financial terms of the agreement have not been disclosed.

Glaukos Corporation (GKOS) reported a 23% increase in net sales for Q1 2021, reaching $68.0 million, compared to $55.3 million in Q1 2020. Key segments included $53.7 million from glaucoma and $14.3 million from corneal health. The gross margin was approximately 76%, significantly up from 41% in the prior year. Operating expenses declined by 17% to $63.1 million, leading to a reduced net loss of $16.5 million or ($0.36) per share. The company projects Q2 2021 revenues between $70 million and $72 million.